Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Oncology

Survivorship: Navigating the Road Ahead and Long-Term Monitoring

At a Glance

After osteosarcoma treatment, survivors follow a strict surveillance schedule including regular chest CT scans to check for recurrence. Lifelong monitoring is also required to manage late effects from chemotherapy, such as heart, hearing, and kidney issues.

Finishing treatment for osteosarcoma is a monumental milestone, but it also marks the beginning of a new phase: survivorship. This period involves moving from active treatment to a structured schedule of monitoring. The goals are twofold: to detect any signs of the cancer returning as early as possible and to manage “late effects”—health challenges that can appear months or even years after treatment ends [1][2].

Your Surveillance Schedule

The first two years after treatment are the most critical, as this is the period when recurrence is most likely to occur [3]. While every hospital’s protocol may differ slightly, the following table represents the standard monitoring schedule recommended by major oncology guidelines [4][5]:

Time Period Frequency of Visits Primary Imaging
Years 1 – 2 Every 3 months Chest CT, X-ray of primary site, Physical Exam
Years 3 – 5 Every 6 months Chest CT or X-ray, Physical Exam
Years 5 – 10 Annually Chest X-ray, Physical Exam, Blood Work
Years 10+ Long-term follow-up Lifelong screening for late effects

Because the lungs are the most common site for osteosarcoma to reappear, the Chest CT remains the most important tool for early detection [6][7].

Managing “Late Effects” of the MAP Regimen

The same drugs that successfully fought the cancer (Methotrexate, Adriamycin, and Platinol) can leave a lasting impact on healthy organs. This makes lifelong monitoring essential [1].

The Heart (Cardiotoxicity)

Doxorubicin (the “A” in MAP) is known to potentially weaken the heart muscle [8]. This can lead to issues with heart function years down the road.

  • Monitoring: Survivors should have regular echocardiograms (ECHO) or Cardiac MRIs to check how well the heart is pumping blood [9][10].

Hearing (Ototoxicity)

Cisplatin (the “P” in MAP) can cause permanent, high-frequency hearing loss or ringing in the ears (tinnitus) [11].

  • Monitoring: Periodic audiograms (hearing tests) are necessary to detect any changes, which can sometimes occur even after treatment has stopped [12][13].

The Kidneys (Nephrotoxicity)

Both Cisplatin and Methotrexate are processed through the kidneys and can cause long-term “wear and tear” on these organs [14].

  • Monitoring: Regular blood and urine tests to check renal function (such as GFR and creatinine levels) are part of standard follow-up care [15].

Navigating “Scanxiety” and Quality of Life

It is completely normal for parents and patients to feel intense stress in the days leading up to and following a surveillance scan—a phenomenon often called scanxiety [16].

  • Understanding the Feeling: Scanxiety is a recognized psychological challenge that peaks during the “waiting period” for results [17].
  • Coping Strategies: Many families find it helpful to plan “distraction days” around scan dates or to use relaxation techniques. If anxiety becomes overwhelming, speaking with a counselor who specializes in oncology can provide effective tools, such as Cognitive Behavioral Therapy (CBT), to manage the distress [18][19].

Despite these challenges, many osteosarcoma survivors go on to live full, active lives. Having a clear Survivorship Care Plan—a document that summarizes all treatments received and the specific tests needed for the future—is the best way to ensure your child stays healthy in the years to come [20].

Common questions in this guide

How often do osteosarcoma survivors need follow-up scans?
During the first two years after treatment, survivors typically have scans every three months. This frequency decreases to every six months in years three through five, and annually thereafter.
Why are chest CT scans so important after osteosarcoma treatment?
The lungs are the most common area for osteosarcoma to return. Regular chest CT scans are the most effective tool for detecting any signs of recurrence as early as possible.
What are the long-term side effects of the MAP chemotherapy regimen?
The MAP chemotherapy regimen can cause late effects that appear years after treatment. These may include heart weakness from doxorubicin, permanent hearing loss from cisplatin, and kidney damage from both cisplatin and methotrexate.
How is heart health monitored in osteosarcoma survivors?
Survivors who received doxorubicin need lifelong heart monitoring. This is typically done using regular echocardiograms or cardiac MRIs to ensure the heart muscle continues to pump blood effectively.
What is a Survivorship Care Plan?
A Survivorship Care Plan is a personalized document that summarizes all the cancer treatments a patient received. It also outlines the specific medical tests and screenings they will need in the future to monitor for recurrence and late effects.
How can families cope with scanxiety?
Scanxiety is the normal intense stress experienced before and after surveillance scans. Families can cope by planning distraction days, practicing relaxation techniques, or working with an oncology counselor using Cognitive Behavioral Therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.When can we expect to receive a formal 'Survivorship Care Plan' summarizing our child's cumulative doses and recommended screening?
  2. 2.Based on the cumulative dose of doxorubicin our child received, how often should we schedule follow-up echocardiograms?
  3. 3.Are there specific signs of hearing loss or kidney issues we should watch for at home between appointments?
  4. 4.How long will our child need to continue having chest CT scans, and can we eventually switch to X-rays to reduce radiation?
  5. 5.Does the hospital offer any psychological support specifically for dealing with 'scanxiety'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Long-term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS).

    Becktell K, Chen Y, Yasui Y, et al.

    Pediatric blood & cancer 2024; (71(10)):e31189 doi:10.1002/pbc.31189.

    PMID: 39010279
  2. 2

    Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment.

    Goedhart LM, Ho VKY, Ploegmakers JJW, et al.

    Journal of bone oncology 2023; (38()):100466 doi:10.1016/j.jbo.2022.100466.

    PMID: 36578650
  3. 3

    Follow-up practices for high-grade extremity Osteosarcoma.

    Rothermundt C, Seddon BM, Dileo P, et al.

    BMC cancer 2016; (16()):301 doi:10.1186/s12885-016-2333-y.

    PMID: 27154292
  4. 4

    Follow-Up in Bone Sarcoma Care: A Cross-Sectional European Study.

    Goedhart LM, Leithner A, Ploegmakers JJW, Jutte PC

    Sarcoma 2020; (2020()):2040347 doi:10.1155/2020/2040347.

    PMID: 32675939
  5. 5

    The significance of surveillance imaging in children with Ewing sarcoma and osteosarcoma.

    Brekke SG, Lucke A, Hasle H, Baad-Hansen T

    Pediatric hematology and oncology 2024; (41(4)):273-282 doi:10.1080/08880018.2024.2311407.

    PMID: 38345039
  6. 6

    Osteosarcoma Metastasis to the Thorax: A Pictorial Review of Chest Computed Tomography Findings.

    Alduraibi KA, Towhari JA, Alebdi HA, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(18)) doi:10.3390/diagnostics14182085.

    PMID: 39335763
  7. 7

    Osteosarcoma.

    Beird HC, Bielack SS, Flanagan AM, et al.

    Nature reviews. Disease primers 2022; (8(1)):77 doi:10.1038/s41572-022-00409-y.

    PMID: 36481668
  8. 8

    Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity.

    Ma W, Wei S, Zhang B, Li W

    Frontiers in cell and developmental biology 2020; (8()):434 doi:10.3389/fcell.2020.00434.

    PMID: 32582710
  9. 9

    Beyond ejection fraction: cardiac magnetic resonance imaging in anthracycline cardiotoxicity.

    Motevalli M, Deilami T, Kia YM, et al.

    BMC medical imaging 2025; (25(1)):478 doi:10.1186/s12880-025-02027-y.

    PMID: 41257577
  10. 10

    Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.

    Bhagat A, Kleinerman ES

    Advances in experimental medicine and biology 2020; (1257()):181-192 doi:10.1007/978-3-030-43032-0_15.

    PMID: 32483740
  11. 11

    A Tumor-Bearing Mouse Model of Cisplatin-Induced Hearing Loss for Preclinical Otoprotectant Evaluation.

    Li X, Mao H, Feng M, et al.

    Hearing research 2026; (477()):109657 doi:10.1016/j.heares.2026.109657.

    PMID: 42143864
  12. 12

    Systemic cisplatin increases the number of patients showing positive off-frequency masking audiometry.

    Hiraumi H, Oikawa SI, Shiga K, Sato H

    PloS one 2023; (18(7)):e0287400 doi:10.1371/journal.pone.0287400.

    PMID: 37410731
  13. 13

    Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

    Clemens E, van den Heuvel-Eibrink MM, Mulder RL, et al.

    The Lancet. Oncology 2019; (20(1)):e29-e41 doi:10.1016/S1470-2045(18)30858-1.

    PMID: 30614474
  14. 14

    Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).

    Shkalim-Zemer V, Ash S, Toledano H, et al.

    Cancer chemotherapy and pharmacology 2015; (76(5)):909-16 doi:10.1007/s00280-015-2865-x.

    PMID: 26365289
  15. 15

    Therapeutic potential and pharmacological mechanisms of cannabinoids in alleviating chemotherapy-induced organ toxicity and adverse effects.

    Zia B, Nagoor Meeran MF, Sharma C, et al.

    European journal of pharmacology 2026; (1017()):178646 doi:10.1016/j.ejphar.2026.178646.

    PMID: 41655682
  16. 16

    Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

    Bui KT, Kiely BE, Dhillon HM, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

    PMID: 34333717
  17. 17

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  18. 18

    Evaluating the efficacy of a self-guided Web-based CBT intervention for reducing cancer-distress: a randomised controlled trial.

    Beatty L, Koczwara B, Wade T

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016; (24(3)):1043-51 doi:10.1007/s00520-015-2867-6.

    PMID: 26248651
  19. 19

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038
  20. 20

    Cardiovascular toxicity in testicular germ cell tumor survivors.

    Orszaghova Z, Mladosievicova B, Mego M, Chovanec M

    Frontiers in oncology 2025; (15()):1654063 doi:10.3389/fonc.2025.1654063.

    PMID: 40881865

This page provides general information about osteosarcoma survivorship and long-term monitoring. Always consult your oncology team for your specific Survivorship Care Plan and follow-up schedule.

Get notified when new evidence is published on Osteosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.